Jonathan A. Ledermann, MD, and Ursula A. Matulonis, MD, on Olaparib Maintenance Monotherapy for Ovarian Cancer 
    		2016 ASCO Annual Meeting
    	
    	
    	
    
        Jonathan A. Ledermann, MD, of Cancer Research UK and University College London Cancer Trials Centre, and Ursula A. Matulonis, MD, of the Dana-Farber Cancer Institute, discuss findings on overall survival in patients with platinum-sensitive relapsed serous ovarian cancer receiving olaparib maintenance monotherapy (Abstract 5501).
    
    
    
    
       
       
    		
		
		
        
		
		
		
		Hope S. Rugo, MD, of the University of California, San Francisco, discusses phase III study results on a new possible alternative to trastuzumab for HER2-positive metastatic breast cancer: the biosimilar known as Myl-1401O (Abstract LBA503).
			
			
     	
    
       
       
    		
		
		
        
		
		
		
		Newly elected ASCO President Daniel F. Hayes, MD, of the University of Michigan Health System Comprehensive Cancer Center, talks about his vision for the society during his tenure.
			
			
     	
    
       
       
    		
		
		
        
		
		
		
		Michele Cavo, MD, of the Seràgnoli Institute of Hematology, Bologna University School of Medicine, discusses results from this phase III study of upfront autologous stem cell transplantation vs novel agent-based therapy for multiple myeloma (Abstract 8000). To see the Italian version of this interview, please click here.
			
			
     	
    
       
       
    		
		
		
        
		
		
		
		James Kochenderfer, MD, of the National Cancer Institute, discuss results of a small study on genetically modified CAR-T cells, which may well become a standard lymphoma treatment (Abstract LBA3010).
			
			
     	
    
       
       
    		
		
		
        
		
		
		
		Yousuf Zafar, MD, of Duke Cancer Institute, summarizes his educational lecture on the financial toxicities of treatment and the need to focus on both short- and long-term interventions to reduce the burden on patients.